Navigation Links
Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Date:12/11/2011

treatment group achieved an objective response to therapy (previously reported as 48%), and 44 percent of the patients in the 840 mg cohort achieved an objective response at six months follow-up. An additional 19 percent of the 420 mg cohort and 35 percent of the 840 mg cohort had a nodal partial response, meaning their disease responded to therapy as represented by a 50 percent or greater reduction in lymph node size, but some lymph nodules persisted. Importantly, 82 percent of patients remain on treatment, and only 8 percent have experienced progressive disease.

Two patients discontinued the trial because of adverse events, and six patients required a dose reduction. The most frequently reported adverse events included diarrhea, fatigue, nausea, and ecchymosis (apparent skin bruising). Serious adverse events (SAEs, which are considered relatively common among this immune-compromised patient population) occurred in 38 percent of patients, with 10 percent considered potentially related to treatment. Grade ≥3 severe AEs considered potentially related to treatment occurred in 21 percent of patients. In addition, the majority of patients experienced high lymphocyte count, an event well-documented with this type of treatment, during the first two months of treatment that resolved over time.

"Our results suggest that PC-32765 has the potential to be highly effective and tolerable, and, more importantly, appears to be working well in patients with poor prognoses," said lead author Susan O'Brien, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston. "As we become better equipped to target specific cellular functions, it is our hope that therapies like PCI-32765 will become effective interventions to manage disease in patients with CLL."

Dr. O'Brien will present this study in an oral presentation on Tuesday, December 13, at 8:30 a.m. PST at the San Diego Convention Center in Ballroom 20A.
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Established and Emerging Biotech Clusters
2. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
3. Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications
4. GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot
5. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
6. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
7. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs
8. Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors
9. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
10. Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers
11. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Chelating Agents Market 2014-2018 ... Chelating Agent A chelating agent is a chemical ... ions, thereby forming a metal-ion complex. It reduces ... chemical processes, formulations, and the environment by chelating ...
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... August 27, 2014 According to the ... to reshape the look and feel of markets for ... for higher-quality ingredients will push for more branded, science-backed ... have experienced strong market growth in the last decade ... their food and cosmetics to fit a more ‘wellness’ ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Whitewater, Wis. - The University of Wisconsin-Whitewater has ... what is now known as the Information Technology Infrastructure ... Computer End-User Technologies program, is a product of joint ... will begin this fall semester. It places a far ...
... Metavante Corp., the financial technology subsidiary of Marshall ... June, of Wayne, Pa.-based GHR Systems, Inc. , ... mortgage and consumer finance industries that offers point-of-sale products ... Systems will become a Metavante subsidiary. , ,GHR's client ...
... - Southern Wisconsin's biotech infrastructure has prompted a ... an operating facility that could employ approximately 200 people. ... the southern tier of Wisconsin to manufacture systems used ... CEO Dan Miller. It's a product that company representatives ...
Cached Biology Technology:Whitewater upgrades tech degree program 2Whitewater upgrades tech degree program 3Minneapolis company sets sights on southern Wisconsin 2Minneapolis company sets sights on southern Wisconsin 3
(Date:8/27/2014)... a dreaded bacterium that can be found in both ... 28 persons in Denmark have been infected with ... have died. , The bacterium is notoriously difficult to ... adapt to changes in its surroundings, says Associate Professor ... from the Department of Biochemistry and Molecular Biology, she ...
(Date:8/26/2014)... Researchers at Washington University in St. Louis have developed ... bones prone to tearing or breaking. The technology, which ... patients, one day may help pinpoint minor strains and ... problems occur. , The research is available online Aug. ... Interface , which publishes research at the nexus of ...
(Date:8/26/2014)... obtaining an unprecedented view of a type of ... of neurological illnesses, including Alzheimer,s disease, Parkinson,s disease, ... stroke. , The team of biologists at Cold ... Energy,s Advanced Photon Source at Argonne National Laboratory ... NMDA (N-methyl, D-aspartate) receptor should serve as template ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3
... from McGill/MUHC and the CHUM have been awarded ... Institutes of Health Research (CIHR) to continue their ... during sexual intercourse. The new funding will allow ... and statistician/epidemiologists, to root-out the cause of a ...
... at Case Western Reserve University School of Medicine and University ... (FDA) has approved plans to begin a study to evaluate ... to treat chronic ischemia, a serious form of heart disease. ... to test the safety of the procedure. It will ...
... leading neuroscientist at MIT and one from the University ... Nov. 4 special issue of Science dedicated to the ... "protocortex" theories of brain development are dead. , The ... neurons divided into distinctly separate areas that process particular ...
Cached Biology News:MUHC investigators search for the root of sexual pain in women 2Feds give researchers ok for safety test of adult stem cells in patients with heart disease 2MIT researcher presents new view of how the cortex forms 2
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
... synthetic peptide whose sequences are derived from mouse resistin protein. ... - S - M - P - L - C - ... - D - K - K - I - K - ... used for neutralization and control experiments with the polyclonal antibody that ...
... Imaging System, Basic Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
Biology Products: